Christopher Counter, PhD, associate director of Basic Research, is a member of a group receiving an international Cancer Grand Challenges Grant to investigate origins of cancer.
A DCI breast cancer care team joins forces with a genetics counselor to treat mother with high-risk genetic syndrome; prompting testing and preventative screening for her kids.
DCI medical oncologists Angeles Alvarez Secord, MD, MHSc, and Rafael Gonzalez, MD, & genetics counselor Maggie Frazier, MS, CGC discussed ovarian cancer, in this DCI OHE event for the community.
This OHE-hosted talk featured director of the Patierno/George/Freedman Lab Jennifer Freedman, PhD, and postdocs Tyler Allen, PhD, and Sean Piwarski, PhD.
DCI faculty Michaela Dinan, PhD, on the impact of the Oncotype DX test on HR+ breast cancer patients over 65, treatment disparities, & the latest therapies.
For some patients, targeted therapy is their best shot. The Molecular Tumor Board at DCI is matching more and more patients to approved therapies and clinical trials.
DCI was invited to join the elite international AACR Project GENIE consortium, whose registry contains clinical-grade cancer genomic sequencing data from nearly 71,000 patients & 80 major cancer types.
Carolyn Menendez, MD, FACS, assistant professor of Surgical Oncology has been appointed director of Duke Cancer Institute’s Clinical Cancer Genetics Program.
Research shows link between genomic recurrence score testing, decreased cancer care costs, with certain breast cancer patients who'd otherwise get chemo.
The Symons family has taken the famous song lyric “from sea to shining sea” to an entirely new level. Rather than simply traveling from state-to-state...